telotristat ethyl (xermelo) Report issue

Small molecule Orphan Drug FDA Approved FDA Fast Track FDA Priority Review FDA

Active Ingredient History

  • Now
Telotristat (telotristat etiprate) is an ethyl ester prodrug which is hydrolyzed to its active moiety LP-778902 both in vivo and in vitro. Telotristat etiprate is an orally bioavailable, small-molecule, tryptophan hydroxylase (TPH) inhibitor. It is the first investigational drug in clinical studies to target TPH, an enzyme that triggers the excess serotonin production within metastatic neuroendocrine tumor (mNET) cells leading to carcinoid syndrome. Unlike existing treatments of carcinoid syndrome which reduce the release of serotonin outside tumor cells, telotristat etiprate reduces serotonin production within the tumor cells. By specifically inhibiting serotonin production telotristat may provide patients with more control over their disease. Telotristat etiprate has received Fast Track and Orphan Drug designation from the U.S. Food and Drug Administration and has been granted priority review by the FDA with a Prescription Drug User Fee Act (PDUFA) target action date of February 28, 2017.   NCATS

More Chemistry

Drug Pricing (per unit)

United States

$1106.3875 - $1450.0100
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

lp-778902 | lx1032 | lx1606 | lx-1606 | telotristat | telotristat ethyl | telotristat etiprate | xermelo


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue